Logo image of ADXN

ADDEX THERAPEUTICS LTD (ADXN) Stock Fundamental Analysis

NASDAQ:ADXN - Nasdaq - US00654J2069 - ADR - Currency: USD

8.14  -0.41 (-4.8%)

Fundamental Rating

2

ADXN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ADXN have multiple concerns. ADXN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ADXN had positive earnings in the past year.
ADXN had a negative operating cash flow in the past year.
ADXN had negative earnings in 4 of the past 5 years.
ADXN had a negative operating cash flow in each of the past 5 years.
ADXN Yearly Net Income VS EBIT VS OCF VS FCFADXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

ADXN has a better Return On Assets (95.59%) than 100.00% of its industry peers.
ADXN has a better Return On Equity (109.29%) than 99.48% of its industry peers.
Industry RankSector Rank
ROA 95.59%
ROE 109.29%
ROIC N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ADXN Yearly ROA, ROE, ROICADXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

ADXN has a better Profit Margin (1410.05%) than 100.00% of its industry peers.
The Operating Margin and Gross Margin are not available for ADXN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 1410.05%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXN Yearly Profit, Operating, Gross MarginsADXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

3

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADXN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADXN has been increased compared to 5 years ago.
Compared to 1 year ago, ADXN has an improved debt to assets ratio.
ADXN Yearly Shares OutstandingADXN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
ADXN Yearly Total Debt VS Total AssetsADXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ADXN has an Altman-Z score of -44.63. This is a bad value and indicates that ADXN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -44.63, ADXN is not doing good in the industry: 89.18% of the companies in the same industry are doing better.
ADXN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, ADXN perfoms like the industry average, outperforming 59.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -44.63
ROIC/WACCN/A
WACC5.02%
ADXN Yearly LT Debt VS Equity VS FCFADXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 3.03 indicates that ADXN has no problem at all paying its short term obligations.
ADXN has a Current ratio of 3.03. This is comparable to the rest of the industry: ADXN outperforms 53.09% of its industry peers.
ADXN has a Quick Ratio of 3.03. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
ADXN has a Quick ratio (3.03) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 3.03
ADXN Yearly Current Assets VS Current LiabilitesADXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 168.16% over the past year.
The Revenue for ADXN has decreased by -53.40% in the past year. This is quite bad
ADXN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -32.07% yearly.
EPS 1Y (TTM)168.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-53.4%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-70.6%

3.2 Future

ADXN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.99% yearly.
Based on estimates for the next years, ADXN will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y-1300%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.99%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADXN Yearly Revenue VS EstimatesADXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
ADXN Yearly EPS VS EstimatesADXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.78, the valuation of ADXN can be described as very cheap.
Based on the Price/Earnings ratio, ADXN is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of ADXN to the average of the S&P500 Index (27.91), we can say ADXN is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for ADXN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.78
Fwd PE N/A
ADXN Price Earnings VS Forward Price EarningsADXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADXN Per share dataADXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as ADXN's earnings are expected to decrease with -25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (7/29/2025, 8:00:00 PM)

8.14

-0.41 (-4.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-02 2025-06-02
Earnings (Next)09-01 2025-09-01
Inst Owners1.3%
Inst Owner Change-41.77%
Ins Owners7.58%
Ins Owner ChangeN/A
Market Cap8.70M
Analysts38
Price Target7.61 (-6.51%)
Short Float %0.31%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.78
Fwd PE N/A
P/S 10.84
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)10.5
EY128.99%
EPS(NY)-4.69
Fwd EYN/A
FCF(TTM)-4.06
FCFYN/A
OCF(TTM)-4.06
OCFYN/A
SpS0.75
BVpS9.69
TBVpS9.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 95.59%
ROE 109.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1410.05%
GM N/A
FCFM N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.03
Quick Ratio 3.03
Altman-Z -44.63
F-Score6
WACC5.02%
ROIC/WACCN/A
Cap/Depr(3y)0.97%
Cap/Depr(5y)5.54%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)168.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-1300%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.99%
Revenue 1Y (TTM)-53.4%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-70.6%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y71.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.13%
EBIT Next 3Y5.45%
EBIT Next 5Y5.93%
FCF growth 1Y75.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.11%
OCF growth 3YN/A
OCF growth 5YN/A